23andMe to Slash 40% of Staff

While 23&Me fought valiantly to democratize the healthcare industry, it stretched itself too thin by attempting multiple unproven businesses simultaneousy. By shifting to genetic testing without retaining a strong ancestry-focused service, it was left vulnerable, and ultimately killed by federal regulation. Hopefully, the company can still work on drug development, but only time will tell.